The TRAILBLAZER-Alzheimer (ALZ) trial, comparing donanemab to placebo, met the primary outcome, but imaging abnormalities and infusion-related responses were identified as undesirable outcomes.

(RTTNews) - Eli Lilly and Co. (LLY) said that donanemab met all primary and secondary endpoints for the 6-month primary outcome analysis in the Phase 3 TRAILBLAZER-ALZ 4 study, providing the first ...

NICE decided that two Alzheimer’s drugs are too expensive for their modest benefits and cannot be recommended for NHS use in ...

The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly press release. The treatment slowed decline on ...

Donanemab raised the risk of amyloid-related ... "While these complications and the primary outcome in this analysis are called 'amyloid-related imaging abnormalities,' it's important to recall ...

Eli Lilly and Company has announced that donanemab met all primary and secondary endpoints for the 6-month primary outcome analysis in the phase 3 TRAILBLAZER-ALZ 4 study, providing the first active ...

It finished enrolling in August 2024. Previously, the company had reported that participants will receive nine monthly infusions of donanemab or placebo, with the primary outcome being time to ...

You basically are going to continue it forever, but donanemab, at least in the trial ... The medication met its primary outcome and had a significant slowing of cognitive and functional decline ...

donanemab met all primary and secondary endpoints for the six-month primary outcome analysis. The data were presented at the 15th Clinical Trials on Alzheimer's Disease conference. The data ...

Lenzer and Brownlee also describe how the main (primary) outcome of the donanemab trials was changed during the trial from the widely accepted "clinical dementia rating scale - sum of boxes" (CDR ...

I read that in a Phase 3 clinical trial, “Donanemab slowed clinical decline by 35% compared to placebo on the primary outcome measure and resulted in 40% less decline in the ability to perform ...